LONDON (Alliance News) - Regenerative medical devices company Tissue Regenix Group PLC on Wednesday reported progress in the US, as its DermaPure product secured further Medicare coverage and its SurgiPure product was given marketing approval.
The group said it has secured further Medicare coverage for its DermaPure treatment for chronic and acute wounds. The product now is covered by 9 of the 11 Medicare administrators, Tissue Regenix said.
Medicare is the federal insurance programme for the over-65s in the US, which subsidises the cost of medical treatment through a reimbursement system.
Tissue Regenix also said it has secured 510k market clearance from the US Food & Drug Administration for SurgiPure XD, clearing the product for a commercial launch in the US this year.
SurgiPure is used to reinforce soft tissue and for the surgical repair of damaged or ruptured soft tissue.
Shares in the company were up 6.3% to 17.00 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Tissue Regenix Group (TRX)